ArticleFrontiers in pharmacology2026
Distribution of
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tolerance to thiopurine drugs is modulated by polymorphisms in the TPMT and NUDT15 pharmacogenes, affecting the activity of the encoded TPMT and NUDT15 enzymes. A recent study disclosed a significant impact of the NUDT15 rs147390019 single nucleotide variant (SNV) on thiopurine tolerance in acute lymphoblastic leukemia patients, self-identified as Hispanic/Latino. Native American (Amerindigenous) ancestry accounts almost exclusively for the presence of rs147390019 in Admixed Americans. We assessed the impact of rs147390019 (NUDT15*4) on the genotype-predicted risk of thiopurine intolerance in three Indigenous cohorts from reservation areas in the Brazilian Amazon, namely Munduruku (n = 77), Paiter-Suruí (n = 81) and Yanomami (n = 90). Methods: The individuals were genotyped using a panel of ancestry-informative markers and a validated TaqMan assay for the rs147390019 polymorphism. Results: The median proportion of Native ancestry in the cohorts was >99%. The rs147390019 SNP was not detected in Yanomami, but was present in Munduruku and Paiter-Suruí at the highest frequencies reported worldwide (0.130 and 0.191, respectively). Carriage of rs147390019 had a major effect on the distribution of inferred NUDT15 and combined NUDT15/TPMT metabolic phenotypes, such that the CPIC guideline recommendations for thiopurine dosing adjustments would apply to 29.9% and 70.4% of the Munduruku and Paiter-Suruí cohorts, respectively. Discussion: The results provide strong evidence to support inclusion of rs147390019 in pharmacogenetic testing panels to guide thiopurine dosing adjustments in Native and Latin American populations, acknowledging their ample genetic diversity and underrepresentation in pharmacogenetic research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.